Insect peptides as novel compounds against Candida spp. infections
DOI:
https://doi.org/10.48797/sl.2025.341Keywords:
PosterAbstract
Background: Candida spp. infections are increasing all over the world, as well as antifungal resistance, highlighting the urgent need for new therapeutic strategies. Previously, several in silico studies have identified insect peptides as potential antifungal drugs – BLAP-6 (from Blaps rhychopetera) and Gomesin (from Acanthoscurria gomesiana) against different fungal species. Objective: The present study aimed to evaluate the antifungal activity of both peptides on Candida spp.. Methods: The evaluation was conducted using several methods, including disk diffusion, minimum inhibitory concentration (MIC), minimum biofilm eradication concentration (MBEC) (EUCAST guidelines), and biofilm biomass quantification by crystal violet staining. Results: MIC and MBEC assays showed that Gomesin has potent antifungal activity at lower concentrations (270 mg/L), achieving total biofilm eradication for most species, except C. glabrata. BLAP-6 exhibited moderate antifungal effects, with some tolerance/resistance profiles observed. Conclusions: BLAP-6 and Gomesin are promising drug candidates suitable for the treatment of Candida spp. infections. Furthermore, some species showed some tolerance/resistance to BLAP-6; therefore, the study of mechanisms involved should be seen as an important future perspective.References
1. Soriano, A. et al. Invasive Candidiasis: Current Clinical Challenges and Unmet Needs in Adult Populations. Journal of Antimicrobial Chemotherapy 2023, 78, 1569–1585, doi: 10.1093/JAC/DKAD139.
2. Silva, S. et al. Candida Species Biofilms’ Antifungal Resistance. Journal of Fungi 2017, 3, 8, doi:10.3390/JOF3010008.
3. Sahoo, A. et al. Target-specific binding efficacy, drug chemistry and pharmacological insights and of insect-derived antifungal peptides in the management of Candida sp. infections (submitted).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Catarina A. M. Sousa, Francisco A. M. Silva, Célia Fortuna Rodrigues
This work is licensed under a Creative Commons Attribution 4.0 International License.
In Scientific Letters, articles are published under a CC-BY license (Creative Commons Attribution 4.0 International License), the most open license available. The users can share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as they give appropriate credit, provide a link to the license, and indicate if changes were made (read the full text of the license terms and conditions of use).
The author is the owner of the copyright.
